
Vaxcell-Bio is an anti-cancer immunotherapy biotech building NK, CAR, and targeted therapy platforms.
vaxcell-bio.comCrawled Nov 16, 2026
BaxcelBio is a South Korean biotech company that researches and develops anticancer immunotherapy. It lists as a Kosdaq growth enterprise and develops small-molecule targeted anticancer drugs, antibody-based new drugs, DDS-based pharmaceuticals, and the veterinary immune adjuvant Baxrukin-15, alongside pet healthcare and pharmaceutical wholesale operations.
BaxcelBio is a South Korean biotech company that researches and develops anticancer immunotherapy. It lists as a Kosdaq growth enterprise and develops small-molecule targeted anticancer drugs, antibody-based new drugs, DDS-based pharmaceuticals, and the veterinary immune adjuvant Baxrukin-15, alongside pet healthcare and pharmaceutical wholesale operations.
LG Energy Solution provides financial gifts to the children of its employees to support their preparation for the 2027 College Scholastic Ability Test. The company aims to ease academic pressure by offering encouragement ahead of the national exam. This initiative reflects LG Energy Solution’s commitment to employee welfare and educational support.
Vaxcellbio finalizes registration of its proprietary natural killer (NK) cell manufacturing technology patent in Korea, targeting liver cancer treatment. The patent covers both the production process and therapeutic application of the NK cells. This marks a key milestone for the company’s oncology-focused pipeline.
Yuhan Corporation now handles domestic sales and distribution of **VaxCell-Bio’s** immune cancer therapy for dogs, **BoxLukin-15**, marking the country’s first such treatment. The move expands access to the veterinary oncology product, which targets cancer in canine patients. VaxCell-Bio developed the therapy, while Yuhan’s distribution network ensures broader availability for pet owners.
Vaxcell-Bio and Cellid have signed a memorandum of understanding (MOU) to collaborate on building a cancer immunotherapy platform. The partnership focuses on advancing antibody-drug conjugates (ADCs) as next-generation treatments for cancer. The companies aim to leverage their expertise to develop innovative therapeutic solutions in the field.
Korean venture capital firms deliver record earnings and strong year-on-year growth driven by strong stock markets and an IPO boom. Both major firms like Korea Investment Partners and smaller players benefit from the favorable conditions. The sector’s performance reflects sustained investor confidence and market liquidity.
South Korean investors are increasingly targeting **tenbagger stocks**—shares in companies delivering over 10x returns. The trend reflects renewed confidence in high-growth equities amid market volatility. Analysts cite improved corporate earnings and sector-specific rallies as key drivers.